top line results for PDD OLE. If safety is confirmed, and dementia, sleep, & parkinsonian movement issues prove to be stablized or improved since the end of ph2 at least for patients with wild type sigma-1 receptors, then A2-73 may be acceptable for NDA submittal.
We must all be continuously on the look out for (BOLO) and signs of possible(REAL) evidence of scientific contradictions. This is the area of learning new things we did not know, we did not know.
Market Data 
Markets 
AI
